GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

NPO-11

Company
Nihon Pharmaceutical Co., Ltd
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Trial details
  • Completed NCT NCT00740324

    Exploratory Study of Additional Use of Scopolamine Butylbromide, Glucagon or NPO-11 Following Single Dose of NPO-11 in Healthy Adult Men

    Not yet reported Nihon Pharmaceutical Co., Ltd 30 participants Est. completion 2009-07 1 site
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT00742599

    Phase III Controlled Clinical Study of NPO-11 in Patients Undergoing Gastric Endoscopy

    Not yet reported Nihon Pharmaceutical Co., Ltd 80 participants Est. completion 2009-07 2 sites
    Other conditions: Patients Undergoing Gastric Endoscopy
    View official trial listing →
  • Completed NCT NCT00745459

    Phase III General Clinical Study of NPO-11 in Patients Undergoing Gastric Endoscopy

    Not yet reported Nihon Pharmaceutical Co., Ltd 100 participants Est. completion 2009-08 4 sites Stand-alone
    Other conditions: Stomach Diseases
    View official trial listing →
  • Completed NCT NCT01411176

    Phase III Study of NPO-11 in Patients Undergoing Therapeutic Upper Gastrointestinal Endoscopy

    Not yet reported Nihon Pharmaceutical Co., Ltd 85 participants Est. completion 2012-06 1 site
    Other conditions: Gastric Cancer
    View official trial listing →
  • Completed NCT NCT01411189

    Phase III Open-labeled Study of NPO-11 in Patients Undergoing Therapeutic Upper Gastrointestinal Endoscopy

    Not yet reported Nihon Pharmaceutical Co., Ltd 33 participants Est. completion 2012-06 1 site
    Other conditions: Gastric Cancer, Colon Nos Polypectomy Tubular Adenoma, Gastric Adenoma
    View official trial listing →
  • Completed NCT NCT03263910

    Study of NPO-11 in Patients Undergoing Gastrointestinal Endoscopy

    Not yet reported Nihon Pharmaceutical Co., Ltd 220 participants Est. completion 2018-08-17 4 sites Stand-alone
    Other conditions: Patients Undergoing Gastrointestinal Endoscopy
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.